Pedí Vaneide Daciane, de França Giovanny Vinícius Araújo, Rodrigues Viviane Bellini, Duailibe Felipe Tavares, Santos Marcella T P, de Oliveira Maria Regina Fernandes
Fundação Oswaldo Cruz, Brasília, Federal District, Brazil.
Faculdade de Medicina, Programa de Pós-Graduação em Medicina Tropical, Universidade de Brasília, Brasília, Federal District, Brazil.
Trop Med Int Health. 2025 Sep;30(9):865-892. doi: 10.1111/tmi.70012. Epub 2025 Jul 22.
This study aimed to investigate the social and economic impacts and disease burden of Chikungunya Fever globally through a systematic literature review.
We performed a comprehensive literature search through MEDLINE (via PubMed), LILACS, and Embase databases, and grey literature, including studies of populations diagnosed with Chikungunya Fever or at risk of infection published in English, Spanish, French, or Portuguese, without date restrictions. Two reviewers independently performed study selection, data extraction, and quality assessment. Methodological quality was assessed using different tools.
Forty-three publications were included. Until 2013, publications originated solely from the Asian and African continents. From 2015 onwards, South America emerged as the predominant source. Publications were classified as cost studies (25), including cost-of-illness (18) and program cost (6); burden of disease studies (10); cost-outcome studies (4), including cost-effectiveness (3) and cost-utility (1); and quality-of-life studies (15). Reported total direct costs associated with Chikungunya Fever ranged from US$ 3.5 million (US Virgin Islands, 2014-2015) to US$ 83.6 billion (Region of the Americas, 2013-2015). Direct medical costs varied from US$ 308.94 (Tamil Nadu, India, 2006) to US$ 33.7 million (Réunion Island, 2005-2006). Vector control program costs ranged from US$ 888,000 annually (Greece, 2013-2017) to US$ 466 million (Brazil, 2016). Estimated disability-adjusted life years per 100,000 population ranged from 4.53 (India, 2006) to 2432 (Region of the Americas, 2013-2015). Quality-of-life studies demonstrated substantial declines across multiple domains, indicating significant functional impairment due to Chikungunya Fever.
Chikungunya Fever imposes a considerable economic and social burden, surpassing that of other endemic arboviral diseases such as dengue and yellow fever. These findings underscore the need for further research to accurately quantify the full scope of Chikungunya Fever-related costs and impacts on affected populations.
本研究旨在通过系统的文献综述,调查全球基孔肯雅热的社会经济影响和疾病负担。
我们通过MEDLINE(经由PubMed)、LILACS和Embase数据库以及灰色文献进行了全面的文献检索,包括以英文、西班牙文、法文或葡萄牙文发表的关于诊断为基孔肯雅热或有感染风险人群的研究,无日期限制。两名评审员独立进行研究选择、数据提取和质量评估。使用不同工具评估方法学质量。
纳入了43篇出版物。直到2013年,出版物仅来自亚洲和非洲大陆。从2015年起,南美洲成为主要来源。出版物分为成本研究(25篇),包括疾病成本(18篇)和项目成本(6篇);疾病负担研究(10篇);成本结果研究(4篇),包括成本效益(3篇)和成本效用(1篇);以及生活质量研究(15篇)。报告的与基孔肯雅热相关的总直接成本从350万美元(美属维尔京群岛,2014 - 2015年)到836亿美元(美洲地区,2013 - 2015年)不等。直接医疗成本从308.94美元(印度泰米尔纳德邦,2006年)到3370万美元(留尼汪岛,2005 - 2006年)不等。病媒控制项目成本从每年88.8万美元(希腊,2013 - 2017年)到4.66亿美元(巴西,2016年)不等。每10万人口估计的伤残调整生命年从4.53(印度,2006年)到2432(美洲地区,2013 - 2015年)不等。生活质量研究表明多个领域有大幅下降,表明基孔肯雅热导致了显著的功能损害。
基孔肯雅热带来了相当大的经济和社会负担,超过了登革热和黄热病等其他地方性虫媒病毒疾病。这些发现强调需要进一步研究,以准确量化与基孔肯雅热相关的成本及其对受影响人群的全面影响。